Jacobs Levy Equity Management, Inc Eye Point Pharmaceuticals, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $21.8 Billion
- Q1 2024
A detailed history of Jacobs Levy Equity Management, Inc transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 43,761 shares of EYPT stock, worth $380,720. This represents 0.0% of its overall portfolio holdings.
Number of Shares
43,761
Previous 43,761
-0.0%
Holding current value
$380,720
Previous $1.01 Million
10.58%
% of portfolio
0.0%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding EYPT
# of Institutions
176Shares Held
53.9MCall Options Held
764KPut Options Held
1.57M-
Cormorant Asset Management, LP Boston, MA6.89MShares$60 Million8.2% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA4.76MShares$41.4 Million0.19% of portfolio
-
Suvretta Capital Management, LLC New York, NY3.76MShares$32.7 Million3.33% of portfolio
-
Franklin Resources Inc San Mateo, CA3.39MShares$29.5 Million0.02% of portfolio
-
Black Rock Inc. New York, NY2.79MShares$24.3 Million0.0% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $296M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...